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Background
epression occurs commonly, but not inevitably,
in patients with cancer at the end of life. Although there
are over 7 million cancer deaths around the world each
year,
1 estimates of the prevalence of depression in ter-
minally ill cancer patients are imprecise. Most studies of
comorbid cancer and depression either make no dis-
tinction between cancer phases (eg, newly diagnosed,
active treatment, survivorship, stable metastatic disease,
end-stage) or fail to operationally define “end-of-life”
care. Consequently, reported prevalence rates for
depression in patients with cancer span a broad range.
Best estimates are that between 15% and 50% of cancer
patients experience depressive symptoms, and 5% to
20% will meet various diagnostic criteria for major
depressive disorder.
2-7
Similarly, few data are available with respect to the fre-
quency with which cancer patients are appropriately
treated for depression at the end of life.
8,9 Only a small
number of controlled clinical trials have been conducted
with depressed cancer patients, whether or not they are
in a terminal phase of their illness. Accordingly, the scope
and magnitude of suffering due to unrecognized and
inadequately treated depression in terminally ill cancer
patients remains both unknown and unfortunate.
Research findings on end-of-life cancer care do not paint
an entirely bleak picture. Incurable cancer represents the
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Patients with cancer and depression experience more
physical symptoms, have poorer quality of life, and are
more likely to have suicidal thoughts or a desire for
hastened death than are cancer patients who are not
depressed. Despite the ubiquity of depressive symp-
toms in cancer patients at the end of life, critical ques-
tions remain unanswered with respect to etiopatho-
genesis, diagnosis, and treatment of depression in
these vulnerable patients. The pharmacotherapy of
depression in patients with advanced cancer should be
guided by a palliative care approach focused on symp-
tom reduction, irrespective of whether the patient
meets diagnostic criteria for major depression. Earlier
and more intensive supportive care for patients with
cancer reduces symptom burden and may prolong life
for patients with advanced disease. Symptom-oriented
clinical trials are needed to improve end-of-life cancer
care.  
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PAGES_11_AG_1040_BA.qxd:DCNS#48  5/03/11  11:36  Page 101paradigmatic existential crisis and thus an opportunity for
individual reflection and interpersonal communion.
Several promising lines of investigation have demon-
strated the benefits of meaning-oriented psychological
therapies and palliative care interventions on quality, and
perhaps duration, of life for end-stage cancer patients.
10-13
Taken together, these data suggest two important con-
clusions: (i) despite the widely held sentiment that
depression is both an unavoidable and “appropriate”
response to the dying process, most terminal cancer
patients do not meet diagnostic criteria for major
depression but can still benefit from medical and psy-
chosocial interventions; and (ii) depressive symptoms,
when they do complicate terminal cancer care, warrant
accurate diagnosis and aggressive treatment to reduce
the substantial suffering of these patients. 
This article reviews several ways in which depression
impacts end-of-life care for adults with cancer. Specific
topics include the diagnosis of depression in seriously ill
cancer patients; the co-occurrence of depression and
somatic symptoms; the impact of depression on the course
of illness; depression and decision-making capacity; sui-
cide; desire for hastened death; treatment of depression in
patients with advanced cancer; and recent research in pal-
liative care that is relevant to depression at the end of life. 
Diagnosis of depression in patients with
advanced cancer
Optimum end-of-life care for cancer patients requires an
ability to make an accurate diagnosis of depression. The
frequency with which depression is both underdiagnosed
(eg, dismissed as a normal and anticipated response to
illness or not considered at all) and misdiagnosed (eg,
mistaken for delirium or poorly controlled pain) in the
oncology setting is a manifestation of the clinical com-
plexity of patients dying from cancer.
14The patient with
widely metastatic cancer who is enduring chemotherapy
and radiation treatment is more likely than not to expe-
rience sleep disturbance, fatigue, anorexia, and weight
loss, whether a depressive syndrome is present or absent. 
Whereas the failure to recognize depression can result
in needless suffering, misdiagnosis can cause avoidable
harm by means of inappropriate pharmacological treat-
ment. The most frequent and consequential example of
this diagnostic and pharmacological mismanagement is
delirium. Hypoactive delirium is the most common sub-
type of delirium, and particularly likely to be mistaken
for depression.
15-21 Prescribing an antidepressant or a psy-
chostimulant to a patient who is withdrawn as a result of
delirium, rather than depression, is more likely to exac-
erbate the delirium than alleviate depressive symptoms.
Avoiding this common clinical error is particularly
important for the terminal cancer patient, as the preva-
lence of delirium can approach 90% in the final days
before death.
17,22,23 For some clinicians, it is tempting to
view the relatively calm, confused state of hypoactive
delirium as a desirable way to die. However, delirium at
the end of life can be deeply distressing to patients, fam-
ily members, and caregivers.
24,25 Terminal delirium also
interferes with a patient’s ability to participate in their
care and say goodbye to loved ones. 
Chemotherapy and other medications used in cancer
treatment (eg, glucocorticoids, narcotics, benzodi-
azepines, antihistamines, and antibiotics) often lead to
adverse effects that mimic depression. Notably,
dopamine-blocking antiemetics such as metoclopramide
(Reglan), prochlorperazine (Compazine), and promet-
hazine (Phenergan) cause akathisia, which may in turn
be misdiagnosed as an anxious or agitated depression.
26,27
Clinicians are thus faced with the task of differentiating
somatic symptoms that masquerade as depression from
a superimposed syndromal depression that complicates
the course and treatment of cancer. Not surprisingly,
even experienced psycho-oncologists struggle with this
difficult determination. 
Even when physiological and pharmacological mimics
of depression have been ruled out, clinicians confront
several additional diagnostic dilemmas. Dying patients
can experience a broad spectrum of depressive symp-
toms, ranging from transient sadness to psychotic
depression. In contrast to the countless studies of
depressive phenomenology in patients without medical
comorbidity, there has been little research in the oncol-
ogy setting to help clinicians distinguish between major
depressive disorder, adjustment disorder with depressed
mood, mood disorder due to a general medical condi-
tion, pathological grief, demoralization, and subsyndro-
mal depressive symptoms.
28-31
Given this diagnostic complexity, it is therefore not sur-
prising that estimates of depression in the oncology set-
ting vary so widely. It is likely that the prevalence of
major depressive disorder increases with advanced
stages of cancer
3,4 and varies by tumor site.
32,33 However,
all cancer types are associated with a rate of depression
that is significantly higher than the general population.
Clinical research
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and course of cancer
Patients with terminal cancer suffer from an enormous
symptom burden. A recent review of 44 studies, including
data from thousands of patients, estimated symptom
prevalence in individuals with incurable cancer.
34 Five
symptoms (fatigue, pain, lack of energy, weakness, and
appetite loss) were reported in greater than 50% of
patients. The prevalence of nervousness and depression
were 48% and 39%, respectively. As described earlier,
many of the core diagnostic symptoms of depression are
precisely those symptoms experienced most commonly
by cancer patients at the end of life.
34 Importantly, somatic
symptoms frequently co-occur with depression in cancer
patients and are associated with increased disability.
35
It is now well-established that depression is an indepen-
dent predictor of mortality in patients with coronary
heart disease.
36 Could a similar effect of depression be
true for patients with cancer as well? A meta-analysis by
Satin and colleagues
37 published in 2009 suggests that
depression may predict mortality in cancer patients. Out
of 9417 patients, those with depressive symptoms had a
26% greater mortality, and those diagnosed with major
depressive disorder had a 39% higher mortality, an
effect that was independent of other risk factors. In a ret-
rospective cohort study of women with breast cancer,
Danish investigators observed a modest, cancer phase-
dependent increase in mortality in women who had pre-
operative or postoperative depression.
38 A smaller ret-
rospective study of patients with malignant brain
astrocytomas found that preoperative depression was
independently associated with decreased survival at 12
and 20 months.
39 To be sure, these observations require
confirmation in larger, prospective studies. Furthermore,
even if a negative prognostic effect of depressive symp-
toms is established for cancer, it will need to be demon-
strated that the early detection and successful treatment
of depression positively impacts survival. Until then, the
most compelling rationale for depression screening and
treatment remains the clinical imperative to relieve suf-
fering and improve functioning. 
Depression and decision-making
Modern cancer care presents patients with challenging
decisions that begin with screening tests (eg, serum pro-
static specific antigen levels, BRCA1 status) and con-
tinue through end-of-life care. As death approaches,
patients and their caregivers are frequently faced with
treatment options that hold diminishing chances of ben-
efit and escalating likelihood of toxicity. Making these
choices is particularly difficult when decision-making is
colored by physical discomfort, existential fear, or
depression. Not surprisingly, a patient’s decision to dis-
continue active cancer treatment is a common trigger for
psychiatric assessment of depression. 
Basic components of decision-making capacity (DMC)
include knowledge, intellectual skills, memory, attention,
concentration, conceptual organization, and aspects of
“executive function” such as the ability to plan, solve
problems, and make probability determinations. Most of
the psychiatric literature on DMC is focused on these cog-
nitive functions and employs psychometric approaches to
the study of subjects with neuropsychiatric illnesses such
as dementia, psychosis, major depression, and bipolar dis-
order.
40-42 In contrast, the contributions of mood, motiva-
tion, faith, and other influences on risk assessment and
decision-making have received less attention but have
clear implications for end-of-life care. The extent to which
these factors, and less easily quantified concepts like intu-
ition, trust, or ambivalence affect the decision-making
process is not known. Much work remains to be done to
better understand these other determinants of decision-
making; however, it is clear that focusing on cognitive
impairment to the exclusion of mood effects is short-
sighted.
Depression is more likely to influence or compromise a
patient’s decision-making abilities than it is to render them
incapacitated or legally incompetent.
42-46 Competence and
DMC are closely related but distinct constructs.
47 In most
developed countries, adults are presumed legally compe-
tent to make autonomous decisions unless a formal judg-
ment of legal incompetence is rendered. Competence
determinations are typically based on the ability to make
specific decisions at a given point in time (eg, choices con-
cerning medical care, management of finances, designation
of a substitute decision-maker, execution of a will).
Standards for determining competence vary by jurisdic-
tion but are based in large part on clinical assessments of
an individual’s cognitive state and DMC. From a legal per-
spective, a person is either competent to make decisions
for themselves or incompetent to do so, in which case
someone else makes decisions on their behalf. As a prac-
tical matter, dying patients are infrequently subjected to
formal legal competency evaluations. Exceptions may arise
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make medical or financial decisions. More commonly, clin-
ical judgments are used to assign decision-making author-
ity when patients become incapacitated. Silvera and col-
leagues found that more than a quarter of elderly patients
followed in a longitudinal study required surrogate deci-
sion-making at the end of life and that having executed an
advance directive significantly influenced outcomes.
48
A frequently observed phenomenon in end-of-life cancer
care is the differential threshold for concern about DMC,
depending on the degree to which the patient is adherent
to medical recommendations. Patients who refuse a diag-
nostic or therapeutic procedure are often suspected of
having impaired DMC. In contrast, decisionally impaired
patients who are passive and agreeable with requests
from their caregivers rarely engender these same con-
cerns. As described above, the diagnosis of hypoactive
delirium is often missed or not appropriately treated at
the end of life. One of several reasons to diagnose and
aggressively treat delirium (with or without agitation) is
that it may restore DMC and thus allow patients to make
important medical decisions for themselves.
49
In summary, depression produces more subtle distor-
tions in DMC than delirium or psychosis, but refusal of
even life-prolonging treatment by a depressed patient
cannot not be assumed to constitute either suicidality or
lack of competence.
43,50 Consequently, patients should be
strongly encouraged to accept treatment for depression,
but a decision to override a refusal of medical treatment
should be based on a formal assessment of DMC rather
than solely on the basis of depression. 
Cancer and suicide
The association between cancer and suicidal behavior is
neither novel nor surprising. Although it appears that the
absolute numbers of suicides in cancer patients is low,
cancer patients clearly have an elevated relative risk of
both suicidal ideation and completed suicide as com-
pared with both the general population and patients with
other medical illnesses. Depression, pain, debility, hope-
lessness and a sense of being a burden to others have
been identified as key risk factors for suicidal behav-
ior.
51,52 Recently, investigators have queried large data-
bases and employed sophisticated methodology to study
this important clinical problem. These data suggest that
the suicide rate for persons with cancer is at least twice
the rate observed in the general US population.
53-55
Specific patterns of suicide have emerged from these
studies that have direct clinical relevance. There is a dif-
ferential risk of suicide depending on gender and cancer
type, with prostate, gastrointestinal, head and neck, and
lung cancers associated with higher rates.
55-58 Suicide also
tends to be more frequent within the first months after
diagnosis and soon after discharge from the hospital.
59,60
Consequently, the ability to assess depression and sui-
cide risk should be considered a core competency for
clinicians who work with cancer patients. This is partic-
ularly important since oncology clinicians are often
unable to identify depression and other factors that put
their cancer patients at higher suicide risk, and only a
minority of cancer patients are appropriately referred to
mental health professionals.
14,61,62
Desire for hastened death
Few clinical scenarios generate a request for psychiatric
evaluation more predictably than when a patient
expresses a wish to die. Walker et al
63 reported results
from over 3000 patients screened for suicidal ideation in
an outpatient oncology clinic in Edinburgh, Scotland.
Eight percent of patients endorsed thoughts of being
better off dead or having thoughts of hurting themselves
in some way. This communication can be an expression
of countless thoughts and feelings including the follow-
ing: a passive wish to be free of suffering; a worry about
future pain; an expression of need for control; a specific
plan to commit suicide; a rejection of futile life-sustain-
ing treatments (withdrawal of care); an acceptance of
death; an elicitation of help in ending one’s life (physi-
cian-assisted suicide); or a request to be killed (euthana-
sia).
31,64-69 Under any circumstances, an endorsement of
suicidal ideation or a request for an intentionally
arranged death is an expression of distress that warrants
careful clinical assessment. 
Muskin
68 observed that physicians respond to requests to
die by focusing predominantly on determinations of the
patient’s DMC. He argued persuasively that too often
there is inadequate attention to the underlying meaning
and importance of these requests. Whereas competent sub-
jects have the right to refuse life-sustaining treatments
(and in Oregon and Washington in the US, as well as in
Belgium, Luxembourg, and Switzerland, request physician-
assisted suicide), a compassionate and comprehensive psy-
chiatric evaluation can help clarify both the patient’s con-
cerns and the ethically permissible medical options.
Clinical research
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cancer care
Treatment guidelines for major depression in otherwise
medically healthy patients are well established and
include an impressive array of pharmacological and psy-
chotherapeutic interventions. Whether these same treat-
ments are as effective for patients with cancer, especially
those with end-stage cancer, is not known. Psychosocial
interventions for depressed cancer patients have been
more extensively studied than psychopharmacological
treatments. Several psychological interventions have
been either adapted or designed specifically for patients
with cancer. A recent Institute of Medicine report on
psychosocial care of cancer patients provides a compre-
hensive and critical review of these treatments.
70 Of par-
ticular promise are interventions that employ principles
of existential psychology and meaning-centered life
review,
10,12 collaborative care models of care delivery,
71,72
palliative care interventions,
11 and novel technology.
73
Evidence in support of antidepressant pharmacotherapy
in cancer patients is far less robust. The few placebo-con-
trolled trials conducted with depressed cancer patients
have yielded mixed results.
74-77 Furthermore, only one of
these placebo-controlled trials evaluated an antidepres-
sant specifically in patients with advanced cancer.
77
Psychostimulants, used widely in the oncology and 
palliative care settings to treat fatigue, also have a role
in the management of depression in patients with can-
cer. Homsi
78 reported a successful open trial of
methylphenidate for depression in patients with
advanced cancer. 
Current clinical practice for the treatment of depression
in patients with end-stage cancer is to institute empiri-
cal trials of antidepressants using a targeted symptom
reduction approach. A personal or family history of
depression and symptoms of excessive guilt, poor self-
esteem, anhedonia, and ruminative thinking strengthen
the argument for a medication trial. Selection of an anti-
depressant should be based on a number of considera-
tions such as prior treatment response, an optimal match
between the patient’s target symptoms and the adverse-
effect profile of the antidepressant (eg, using a sedating
agent for the patient with anxiety and insomnia), and a
low likelihood of drug-drug interactions (many
chemotherapeutic and antifungal agents are metabolized
by CYP 3A3/4 enzymes. Mirtazapine (Remeron) has
several properties that make it a particularly attractive
antidepressant choice in patients with advanced cancer:
it is sedating, causes weight gain, has few significant drug
interactions, and is a partial 5HT-3 receptor antagonist
(ie, has antiemetic properties). In line with this approach,
the 5-HT-3 receptor blocking properties of mirtazapine
and olanzapine have led some palliative care clinicians
to recommend these agents as first-line medications for
nausea.
79
It is the rare exception for a patient with advanced can-
cer to have depressive symptoms in isolation. Patients
typically have depressive symptoms alongside nausea,
fatigue, pain, and perhaps cognitive impairment. For this
reason, a targeted symptom reduction orientation is pre-
ferred over the practice of using medications only for
patients who meet full diagnostic criteria for depression. 
Recent developments in end-of-life care
End-of-life care remains inadequate for many cancer
patients. Despite major advances in palliative care
research,
80 too many patients with advanced cancer have
to contend with a health care system that is polarized
between active (often “aggressive”) treatment directed
at cure (or prolongation of life)
81-83 or a focus on symp-
tom management, comfort measures, and an explicit
transition to hospice. In the United States, government-
sponsored health care financing rules perpetuate this
binary approach. Medicare pays for cancer treatments
in patients with advanced disease, irrespective of the
number of prior unsuccessful treatments or the likely
effectiveness of additional treatments.
82 Additionally,
patients can only receive the Medicare hospice benefit
if a physician certifies they have 6 months or less to live
and they agree to forgo active treatment. 
Fortunately, recent studies have established important
benefits of advance care planning and palliative care.
Detering and colleagues
84 conducted a randomized trial
comparing advance care planning to usual care with
elderly hospitalized patients. In contrast to prior studies
focused on completion rates of advance directives, the
primary outcome of this study was whether a patient’s
end-of-life wishes were known and respected. Eighty-six
percent of the patients in the advance care planning
group had their end-of-life wishes known and followed,
compared with 30% of the control patients.
Furthermore, family members of patients who died
reported significantly less distress, anxiety, and depres-
sion.
84
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was recently reported from the Massachusetts General
Hospital.
11 Patients with stage IV lung cancer were ran-
domized to receive either usual care or a palliative care
intervention. The intervention focused on assessment of
physical and psychosocial symptoms, establishing goals of
care, assisting with decision-making regarding treatment,
and individualized coordination of care. Patients in the pal-
liative care intervention group experienced improved qual-
ity of life, had less depression and physical symptom burden,
and lived an average of 2.7 months longer than the usual
care group despite receiving less aggressive care. Hopefully,
studies such as these will shape policy decisions and health
care funding mechanisms that promote a more rational and
compassionate approach to end-of-life care, whether
patients continue to receive active cancer treatment or not.
85
Conclusion
Depressive symptoms complicate end-of-life cancer care
by contributing to physical and psychological morbidity.
Depression may also be associated with increased mortal-
ity. Unfortunately, this treatable cause of suffering is fre-
quently misdiagnosed and poorly treated in patients with
cancer who are dying. In addition to traditional psychoso-
cial and pharmacological treatments, several novel
approaches to end-of-life care have been shown to result
in robust improvement in depressive symptoms for
patients with terminal cancer. These comprehensive and
patient-centered interventions offer patients the incalcu-
lable benefits of less suffering and optimum communica-
tion with family, friends, and clinicians providing care for
them at the end of life.  ❏
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La depresión y los cuidados terminales para
pacientes con cáncer
Los pacientes con cáncer y depresión experimentan
más síntomas físicos, tienen una peor calidad de
vida y una mayor probabilidad de tener pensa-
mientos suicidas o deseos de acelerar la muerte que
los pacientes con cáncer sin depresión. A pesar de
la ubicuidad de los síntomas depresivos en los
pacientes con cáncer al final de la vida, persisten
preguntas críticas que no se han respondido en
relación con la etiopatogenia, el diagnóstico y el
tratamiento de la depresión en estos pacientes vul-
nerables. La farmacoterapia de la depresión en
pacientes con cáncer avanzado debe estar guiada
por una aproximación de cuidados paliativos orien-
tada a la reducción de los síntomas, independiente
de si el paciente cumple o no con los criterios diag-
nósticos para una depresión mayor. Las terapias de
soporte más precoces e intensas para los pacientes
con cáncer reducen el peso de los síntomas y pue-
den prolongar la vida para los pacientes con la
enfermedad avanzada. Los ensayos clínicos orien-
tados a los síntomas son necesarios para mejorar los
cuidados del cáncer terminal.
Dépression et soins de fin de vie pour les
patients cancéreux
Les patients présentant un cancer et une dépression
ont plus de symptômes physiques, une qualité de
vie moins bonne, plus de pensées suicidaires ou de
désir de fin de vie accélérée que les patients cancé-
reux non déprimés. Malgré l'omniprésence des
symptômes dépressifs chez les patients cancéreux
en fin de vie, certaines questions essentielles tou-
chant l’étiopathogénie, le diagnostic et le traite-
ment restent sans réponse chez ces patients vulné-
rables. Le traitement pharmacologique de la
dépression chez des patients présentant un cancer
évolué devrait s’effectuer selon une approche pal-
liative centrée sur la diminution des symptômes,
que le patient remplisse les critères diagnostiques
d’une dépression majeure ou non. Une assistance
plus précoce et plus intensive des patients cancé-
reux diminue la charge des symptômes et peut pro-
longer la vie des patients dont la maladie est évo-
luée. Des études cliniques orientées sur les
symptômes sont  nécessaires pour améliorer les
soins de fin de vie au cours du cancer.
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